lox、E-cadherin在涎腺良恶性多形性腺瘤中表达及临床意义  

Expression and Clinical Significance of LOX and E-cadherin in Pleomorphic Adenoma and Malignant Pleomorphic Adenoma

作　　者：赵华[1] 曲学伟[1] 张睿[1] 张宏[1] 李善昌[1] 

机构地区：[1]佳木斯大学口腔医学院,黑龙江佳木斯154002

出　　处：《口腔医学研究》2013年第8期735-738,741,共5页Journal of Oral Science Research

基　　金：黑龙江卫生厅科研课题(编号:2012-224);佳木斯大学科学技术面上项目(编号:L2012-036);佳木斯大学研究生创新科研项目(编号:YJSCX2012-027JD)

摘　　要：目的:探讨抑癌因子赖氨酰氧化酶和E-钙粘附素在涎腺良恶性多形性腺瘤中表达及相关性。方法:用免疫组织化学检测涎腺良性多形性腺瘤,涎腺恶性多形性腺瘤,癌旁正常涎腺组织中lox、E-cad的表达情况。结果:lox、E-cadherin在恶性多形性腺瘤中阳性表达,明显高于良性多形性腺瘤和正常涎腺组织(P<0.01);lox、E-cadherin在恶性多形性腺瘤中有淋巴结转移与无淋巴结转移中不同组织学分级表达阳性率有显著性(P<0.05),lox、E-cadherin在恶性多形性腺瘤中不同临床分型表达阳性率无显著性。lox及E-cadherin表达呈正相关,r=0.7591(P<0.0001)。结论:lox、E-cadherin既是肿瘤抑制因子,也起促进肿瘤转移作用,联合检测可更好的评价恶性多形性腺瘤,为临床诊断及治疗提供依据。Objective： To explore the expression and correlation of ammonia acyl oxidase and E -- calcium adhesion in saliary gland benign and malignant pleomorphic adenoma. Methods： Immunohistochemistry was used to detect 49 cases of salivary gland benign pleomorphic adenoma, 34 cases of salivary gland malignant pleomorphic adenoma, 10 cases of carcinoma with lox and E--cad expression. Results： Lox positive expressed in malignant pleomorphic ade- noma （85.29%）, significantly higher than that of benign pleomorphic adenoma （24.49%）, normal saliary gland tissue （0%）. Lox in malignant pleomorphic adenoma of lymph node metastasis and without lymph node metastasis expression were significant, lox in malignant pleomorphic adenoma in different histological grading expression were significant, lox in malignant pleomorphic adenoma in different clinical classification expression were no significant. lox and E -- cadherin expression were positively correlated （r = 0. 7591）. Conclusion： Both Lox and E cadherin show a positive correlation. They are tumor inhibitory factor, and also promote tumor metastasis. Joint detection can better evaluate malignant pleomorphic adenoma, and provide the basis for the clinical diagnosis and treatment.

关 键 词：涎腺良性多形性腺瘤 涎腺恶性多形性腺瘤 LOX E-CADHERIN 免疫组织化学 

分 类 号：R739.8[医药卫生—肿瘤]